Apellis Pharmaceuticals, Inc. APLS
Set alert
At close · May 15
After hours · May 15, 4:00 PM ET
- YTD
- +63.34%
- 1 year
- +150.79%
- Open
- 41.05
- Prev close
- 41.03
- Mkt cap
- 5.25B
- Vol
- 28.64M
- Avg vol
- 7.54M
- EPS
- 1.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 41.03
- High
- 41.05
- Beta
- -0.25
- Inst. own
- 110.43%
- Dividend
- 0.00
- Earnings
- Jul 30, 2026
5Y chart
Events in this range
- Sep 20, 2024Rating: Needham · Buy → Buy
- Sep 20, 2024Rating: Mizuho · Neutral → Neutral
- Sep 23, 2024Rating: Baird · Outperform → Outperform
- Sep 24, 2024Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 16, 2024Rating: William Blair · — → Outperform
- Oct 16, 2024Rating: Scotiabank · — → Sector Perform
- May 7, 2025Earnings: -0.74; estimate -0.36; surprise -105.56%
- Jul 31, 2025Earnings: -0.33; estimate -0.44; surprise 25%
- Oct 30, 2025Earnings: 1.67; estimate 1.03; surprise 62.14%
- Feb 24, 2026Earnings: -0.47; estimate -0.39; surprise -20.51%
- May 7, 2026Earnings: 0.15; estimate -0.38; surprise 139.47%
Signals (74)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| RSI: Overbought | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 13, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 16, 2025 | 10 months ago |
| SMA: Bullish | Dec 9, 2025 | 10 months ago |
| SMA: Bullish | Dec 9, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| RSI: Oversold | May 9, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| SMA: Bearish | Jan 16, 2025 | 1 year ago |
| SMA: Bullish | Nov 26, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 19, 2024 | 1 year ago |
| MACD: Sell Signal | Sep 30, 2024 | 2 years ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 29, 2024 | 2 years ago |
| SMA: Bearish | Jul 22, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| SMA: Bearish | Apr 12, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 14, 2024 | 2 years ago |
| SMA: Bearish | Feb 29, 2024 | 2 years ago |
| SMA: Bullish | Dec 21, 2023 | 2 years ago |
| SMA: Bearish | Dec 14, 2023 | 2 years ago |
| SMA: Bullish | Dec 7, 2023 | 2 years ago |
| MACD: Buy Signal | Oct 17, 2023 | 3 years ago |
| SMA: Bullish | Sep 12, 2023 | 3 years ago |
| SMA: Bearish | Jul 18, 2023 | 3 years ago |
| RSI: Oversold | Jul 18, 2023 | 3 years ago |
| SMA: Bearish | Jul 11, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 11, 2023 | 3 years ago |
| SMA: Bullish | Jul 3, 2023 | 3 years ago |
| SMA: Bearish | Jun 27, 2023 | 3 years ago |
| RSI: Overbought | Jun 6, 2023 | 3 years ago |
| RSI: Overbought | May 9, 2023 | 3 years ago |
| RSI: Overbought | Apr 4, 2023 | 3 years ago |
| SMA: Bullish | Feb 21, 2023 | 3 years ago |
| SMA: Bullish | Feb 21, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 21, 2023 | 3 years ago |
| SMA: Bearish | Feb 14, 2023 | 3 years ago |
| SMA: Bullish | Jan 17, 2023 | 3 years ago |
| SMA: Bearish | Dec 27, 2022 | 3 years ago |
| SMA: Bullish | Dec 13, 2022 | 3 years ago |
| SMA: Bearish | Nov 8, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 10, 2022 | 4 years ago |
| SMA: Bearish | Sep 26, 2022 | 4 years ago |
| RSI: Overbought | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Jul 25, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 25, 2022 | 4 years ago |
| SMA: Bearish | Jul 18, 2022 | 4 years ago |
| SMA: Bullish | Jun 27, 2022 | 4 years ago |
| SMA: Bullish | Jun 17, 2022 | 4 years ago |
| SMA: Bearish | May 2, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
| SMA: Bearish | Feb 18, 2022 | 4 years ago |
| SMA: Bullish | Feb 7, 2022 | 4 years ago |
| SMA: Bearish | Jan 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 5.25B
- Enterprise value
- 5.32B
- Trailing P/E
- 38.71
- PEG ratio
- 0.07
- Price / sales
- 4.75
- Price / book
- 12.46
- Beta
- -0.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 12.06%
- Total cash
- 0
- Total debt
- 4
- Return on equity
- 39.71%
Analyst view
- Strong buy10
- Buy4
- Hold8
- Sell0
- Strong sell0
Next earnings
Jul 30, 2026
Expected Jul 30, 2026. Consensus EPS estimate -0.33.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 30, 2026 | Jun 30, 2026 | -0.33 | — | — | — |
| May 7, 2026 | Mar 31, 2026 | -0.38 | 0.15 | +0.53 | +139.47% |
| Feb 24, 2026 | Dec 31, 2025 | -0.39 | -0.47 | -0.08 | -20.51% |
| Oct 30, 2025 | Sep 30, 2025 | 1.03 | 1.67 | +0.64 | +62.14% |
| Jul 31, 2025 | Jun 30, 2025 | -0.44 | -0.33 | +0.11 | +25.00% |
| May 7, 2025 | Mar 31, 2025 | -0.36 | -0.74 | -0.38 | -105.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2024 | Scotiabank | init | — | Sector Perform |
| Oct 16, 2024 | William Blair | init | — | Outperform |
| Sep 24, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Sep 23, 2024 | Baird | main | Outperform | Outperform |
| Sep 20, 2024 | Mizuho | main | Neutral | Neutral |
| Sep 20, 2024 | Needham | reit | Buy | Buy |
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 705
- Website
- apellis.com
News
- Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
- Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
- TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
- Why Is Biogen Stock Falling Thursday?
- Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
- Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
- Remitly Global Set To Join S&P SmallCap 600 Will Replace Apellis Pharmaceuticals
- Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
- Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNO
Your note
Sign in to keep a note on APLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOUCHER KELLEY | Officer | Stock Award(Grant) | Jan 27, 2026 | 127,804 |
| DELONG MARK JEFFREY | Officer | Sale | Feb 10, 2026 | 114,591 |
| DESCHATELETS PASCAL | Officer | Stock Award(Grant) | Jan 27, 2026 | 1,177,220 |
| DUNLOP ANDREW SINCLAIR | Director | Stock Award(Grant) | Dec 30, 2025 | 161,567 |
| FRANCOIS CEDRIC | Chief Executive Officer | Stock Gift | Mar 10, 2026 | 1,805,260 |
| LESLIE MELTZER | Officer | Stock Award(Grant) | Jan 27, 2026 | 107,024 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BlackRock Inc | 10.57% | 13,536,964 | 0 | Mar 30, 2026 |
| venBio Select Advisor LLC | 9.55% | 12,222,222 | 0 | Mar 30, 2026 |
| Vanguard Group Inc | 8.34% | 10,674,865 | 0 | Dec 30, 2025 |
| Morgan Stanley - Brokerage Accounts | 7.84% | 10,042,399 | 0 | Mar 30, 2026 |
| State Street Corp | 5.35% | 6,844,990 | 0 | Mar 30, 2026 |
| UBS Group AG | 4.85% | 6,206,681 | 0 | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ossiam Lux-OssiamSerenityErCITSTF1CURAcc | 0.39% | 504,999 | 0 | Oct 30, 2025 |
| International Biotechnology Ord | 0.32% | 412,728 | 0 | Mar 30, 2026 |
| Man Event Driven Alternative IN USD | 0.30% | 386,466 | 0 | Mar 30, 2026 |
| Pictet Biopharmaceutical Mother | 0.27% | 347,708 | 0 | Oct 13, 2025 |
| Russell 1000 Index Non-Lendable Fund B | 0.26% | 337,935 | 0 | Dec 30, 2025 |
| Russell 1000 Index Non-Lendable Fund | 0.26% | 337,935 | 0 | Dec 30, 2025 |